[Editor's Note: A version of this article by Tim Casey originally appeared in In Vivo, Medtech Insight's sister publication, as well as AIS Health’s Health Plan Weeklypublished by Norstella, Medtech Insight'sparent company.]
Prescription digital therapeutics (PDT) companies like Pear Therapeutics, Better Therapeutics and Akili Interactive Labs are facing reimbursement challenges and an investment
Key Takeaways
-
Prescription digital therapeutics (PDTs) companies that went public via SPAC are struggling to stay afloat.
-
The companies and the industry trade group primarily attribute PDTs' disappointing uptake to lack of reimbursement and payers' resistance to innovation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?